<DOC>
	<DOCNO>NCT02315196</DOCNO>
	<brief_summary>This phase II trial study well pegylated liposomal doxorubicin hydrochloride carboplatin follow surgery paclitaxel work treat patient stage II-III breast cancer estrogen receptor , progesterone receptor , large amount human epidermal growth factor receptor 2 ( HER2 ) /neu protein ( triple negative ) . Drugs use chemotherapy , pegylated liposomal doxorubicin hydrochloride , carboplatin , paclitaxel , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving pegylated liposomal doxorubicin hydrochloride carboplatin surgery may make tumor small reduce amount normal tissue need remove . Giving pegylated liposomal doxorubicin hydrochloride carboplatin follow surgery paclitaxel may effective treatment breast cancer .</brief_summary>
	<brief_title>Pegylated Liposomal Doxorubicin Hydrochloride Carboplatin Followed Surgery Paclitaxel Treating Patients With Triple Negative Stage II-III Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine rate pathologic complete response treatment liposomal doxorubicin ( pegylated liposomal doxorubicin hydrochloride ) carboplatin patient estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER2 negative breast cancer ( triple negative breast cancer [ TNBC ] ) . SECONDARY OBJECTIVES : I . To determine recurrence free survival ( RFS ) , 2-year RFS , overall survival ( OS ) treatment neoadjuvant liposomal doxorubicin carboplatin follow definitive breast surgery weekly paclitaxel patient ER , progesterone receptor ( PgR ) , HER2 negative breast cancer . II . To describe mutational spectrum tumor find primary , untreated ER , PgR , HER2 negative breast cancer association pathologic complete response neoadjuvant pegylated liposomal doxorubicin hydrochloride ( doxil ) carboplatin . III . To determine functional significance genomic landscape predict drug response use patient derive xenograft ( PDX ) ex vivo model . OUTLINE : NEOADJUVANT : Patients receive pegylated liposomal doxorubicin hydrochloride* intravenously ( IV ) 90 minute carboplatin IV 30-60 minute day 1 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . ADJUVANT : Patients undergo definitive surgery discretion treat physician . Patients receive paclitaxel IV 60 minute weekly 12 week absence disease progression unacceptable toxicity . *NOTE : If shortage pegylated liposomal doxorubicin hydrochloride , patient receive epirubicin hydrochloride IV 15-20 minute day 1 . After completion study treatment , patient follow every 6 month 20 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Women previously untreated , unilateral stage IIIII breast cancer , ER/PgR/HER2 negative ( ER = &lt; 5 % , PgR = &lt; 5 % , HER2 01+ immunohistochemistry [ IHC ] fluorescence situ hybridization [ FISH ] = &lt; 2.0 ) ; clinically negative lymph node , tumor size minimum 1.0 cm identifiable officebased ultrasound guidance Negative serum urine betahuman chorionic gonadotropin ( hCG ) pregnancy test screening patient childbearing potential within one week prior enrollment Patients reproductive potential must use adequate contraceptive method ( e.g . abstinence , intrauterine device , oral contraceptive , barrier device spermicide surgical sterilization ) treatment three month complete treatment Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Life expectancy &gt; = 52 week exclude diagnosis breast cancer Absolute neutrophil count ( ANC ) &gt; = 1,500 cells/mm^3 Platelets &gt; = 100,000 cells/mm^3 Hemoglobin &gt; 9.0 g/dL Creatinine &lt; 2.5 mg/dL Total bilirubin &lt; 1.5 X upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2.5 X institutional ULN Patients must normal cardiac function , evidence left ventricular ejection fraction ( LVEF ) within institutional normal limit ; echocardiogram may use multi gated acquisition ( MUGA ) scan available , test must use throughout study evaluate LVEF Computed tomography chest , abdomen , pelvis ( CT CAP ) bone scan perform within 30 day prior study entry demonstrate metastatic disease Patients may receive concurrent treatment investigational commercial agent ( ) treatment breast cancer The patient , applicable , legally authorize representative must sign dated Institutional Review Board ( IRB ) approve consent form conform federal institutional guideline Patients must eligible undergo surgery , either lumpectomy mastectomy local treatment breast cancer ; surgical margin discretion surgeon per National Comprehensive Cancer Network ( NCCN ) guideline ; axillary exploration discretion surgeon patient minimally sentinel lymph node evaluation time surgery Imaging magnetic resonance imaging ( MRI ) , ultrasound and/or mammogram physical exam document lesion size must perform within 30 day study entry Must exhibit nonhealing wound skin breakdown Before administer liposomal doxorubicin , patient must wait 46 week surgery Submission tumor sample diagnostic biopsy breast surgery require patient Women pregnant breastfeed Second primary malignancy except situ carcinoma ( e.g . situ carcinoma cervix , adequately treat nonmelanomatous carcinoma skin ) malignancy treat least 5 year previously evidence recurrence Definitive clinical radiologic evidence metastatic disease ; image must perform great 30 day prior initiation chemotherapy Diagnosis inflammatory breast cancer History hypersensitivity reaction attribute conventional formulation doxorubicin hydrochloride ( HCL ) component doxil , paclitaxel , carboplatin Serious concomitant systemic disorder ( include active infection chronic infection require suppressive antibiotic ) would compromise safety patient compromise patient 's ability complete study , discretion investigator Myocardial infarct unstable angina within 6 month enrollment , New York Heart Association ( NYHA ) class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , valvular disease document compromise cardiac function , electrocardiographic evidence acute ischemic active conduction system abnormalities Prior anthracycline , platinum salt , taxane malignancy Known active hepatitis B C abnormal liver function test Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Intrinsic lung disease result moderate severe dyspnea History major organ allograft condition require chronic immunosuppression , e.g. , kidney , liver , lung , heart , bone marrow transplant , autoimmune disease ; include treatment corticosteroid within one month ( dose &gt; = 10 mg/day methylprednisolone equivalent ) ( exclude inhale steroid ) ; patient receive corneal transplant , cadaver skin , bone transplant eligible Nervous system disorder ( paresthesias , peripheral motor neuropathy , peripheral sensory neuropathy ) &gt; = grade 2 , per Common Terminology Criteria Adverse Events version 4.0 ( CTCAE v4.0 ) Conditions would prohibit administration corticosteroid</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>